title: Bone-resorbing activity of thyroid hormones is related to prostaglandin production in cultured neonatal mouse calvaria.
abstract: The bone-resorbing activity of thyroid hormones was evaluated in neonatal mouse calvaria maintained in organ culture for 96 h. Thyroxine (T4) between 10(-8) and 10(-5) mol/liter and triiodothyronine (T3) between 10(-8) and 10(-7) mol/liter caused a dose-dependent release of calcium from cultured bone. The thyroid hormone effect was delayed in onset for at least 24 h, and after 96 h of culture amounted to 50-90% of the bone-resorbing activity of 10(-8) mol/liter parathyroid hormone (PTH). The bone-resorbing action of T4 as well as of T3 was completely blocked by 100 U/ml interferon-gamma (IF-gamma) or 20 mU/ml salmon calcitonin (CT). "Escape" from CT inhibition, which is a well-known phenomenon in the action of PTH, was not observed with thyroid hormone-mediated bone resorption. Thyroid hormone treatment of cultured calvaria resulted in a gradual increase between 48 and 96 h of medium concentrations of prostaglandin (PG) E2 and particularly of 6-keto-PGF1 alpha, the inactive metabolite of prostacyclin (PGI2). The release of PGF2 alpha in general was not significantly affected. Although the effect of thyroid hormones on PG release from cultured calvaria was completely abolished by 5 x 10(-7) mol/liter indomethacin, in some experiments indomethacin reduced thyroid hormone-mediated bone resorption by only 50%. This indicates that thyroid hormone action on bone is also mediated by a PG-independent mechanism.
authors.affiliation: Ludwig Boltzmann Research Unit for Clinical and Experimental Osteology, 4th Medical Department, Hanusch-Hospital, Vienna, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Klaushofer
authors.forename: O
authors.initials: O
authors.lastname: Hoffmann
authors.forename: H
authors.initials: H
authors.lastname: Gleispach
authors.forename: H J
authors.initials: HJ
authors.lastname: Leis
authors.forename: E
authors.initials: E
authors.lastname: Czerwenka
authors.forename: K
authors.initials: K
authors.lastname: Koller
authors.forename: M
authors.initials: M
authors.lastname: Peterlik
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism / Q000502:physiology*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism; D001862:Bone Resorption / Q000187:drug effects; D001842:Bone and Bones / Q000166:cytology / Q000378:metabolism / Q000502:physiology*; D002116:Calcitonin / Q000494:pharmacology; D002478:Cells, Cultured; D015232:Dinoprostone / Q000378:metabolism; D007213:Indomethacin / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D011453:Prostaglandins / Q000096:biosynthesis*; D013974:Thyroxine / Q000502:physiology*; D014284:Triiodothyronine / Q000502:physiology*
chemical_list: D001095:Arachidonic Acids; D011453:Prostaglandins; D014284:Triiodothyronine; D016718:Arachidonic Acid; D015121:6-Ketoprostaglandin F1 alpha; D002116:Calcitonin; D015232:Dinoprostone; D013974:Thyroxine; D007213:Indomethacin